Asia Pacific Ophthalmic Drug Delivery System Market 2021-2031

Asia Pacific ophthalmic drug delivery system market will grow by 8.9% annually with a total addressable market cap of $56,139.1 million over 2022-2031, driven by the growing prevalence of ophthalmic diseases, the emerging novel ocular drug delivery systems, rise in number of ophthalmic procedures that require attentive post procedural care, and the increasing demand to deliver controlled dosage forms for pediatric and geriatric population. Highlighted with 27 tables and 56 figures, this 127-page report “Asia Pacific Ophthalmic Drug Delivery System Market 2021-2031 by Product (Syringes, Eyedroppers, Dispensers, Sprayers, Contact Lenses, Inserts, Implants, Plugs), Dosage Form (Solutions, Gels, Ointments, Suspensions, Emulsions, Liposomes & Nanoparticles), Disease (Glaucoma, Diabetic Retinopathy, Cataract, Dry Eye Syndrome, Macular Degeneration, Diabetic Macular Edema, Refractive Issues), Setting (Hospitals, Clinics, Homecare Settings, ASCs, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific ophthalmic drug delivery system market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific ophthalmic drug delivery system market in every aspect of the classification from perspectives of Product, Dosage Form, Disease, Setting, and Country. Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pre-filled Syringes • Multidose Eyedroppers • Squeeze Dispensers • Mist Sprayers • Contact Lenses • Ocular Inserts • Intraocular Implants • Punctal Plugs • Other Products Based on Dosage Form, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Solutions • Gels • Ointments • Suspensions • Emulsions • Liposomes & Nanoparticles By Disease, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Glaucoma • Diabetic Retinopathy • Cataract • Dry Eye Syndrome • Macular Degeneration • Diabetic Macular Edema • Refractive Issues • Other Diseases By Setting, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals • Clinics • Homecare Settings • Ambulatory Surgical Centers (ASCs) • Other Settings Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Dosage Form, and Setting over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Aero Pump GmbH Allergan plc. AptarGroup, Inc. Becton, Dickinson and Company Biocorp Clearside Biomedical, Inc. EyePoint Pharmaceuticals, Inc. Gaplast GmbH Gerresheimer AG Jotteq Inc. Kedalion Therapeutics, Inc. Mati Therapeutics, Inc. Nemera Nipro Corporation Ocular Therapeutix, Inc. Ocumedic, Inc. Owen Mumford Re-Vana Therapeutics Silgan Holdings Inc. Terumo Corporation Valeant Pharmaceuticals International Inc. (Bausch Health Company) West Pharmaceutical Services, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)